Chorionic gonadotropin market seen reaching $1.82 million by 2030
The Business Research Company says the chorionic gonadotropin market will grow from $1.34 million in 2025 to $1.43 million in 2026, then reach $1.82 million by 2030. The report points to rising infertility, broader use of assisted reproductive technologies and expanding medical applications as the main drivers.
Why it matters: - Chorionic gonadotropin is used in fertility care, male hormone treatment and oncology diagnostics, so market growth tracks demand across multiple medical specialties. - The report ties the market's outlook to rising infertility worldwide, which is pushing more patients toward treatment. - Expanded use in assisted reproductive technologies could broaden demand for the hormone in both fertility clinics and related care settings.
What happened: - The Business Research Company published a 2026 chorionic gonadotropin market report with a forecast through 2035. - The report says the market will rise from $1.34 million in 2025 to $1.43 million in 2026. - The report projects the market will reach $1.82 million by 2030. - North America held the largest regional share of the global market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.
The details: - Chorionic gonadotropin, especially human chorionic gonadotropin or hCG, is a hormone produced by the placenta during pregnancy. - hCG helps maintain progesterone levels by supporting the corpus luteum. - Medical uses include inducing ovulation in women, treating male hypogonadism and serving as a tumor marker for certain cancers. - The report links past growth to infertility treatment demand, the hormone's role in ovulation induction, rising male reproductive issues, hospital fertility programs and long clinical use. - The report says future growth will be supported by rising infertility rates globally, wider adoption of assisted reproductive technologies, greater awareness of male hormonal disorders, expanded use in oncology diagnostics and broader access through retail pharmacy channels. - Expected market trends include increased use in fertility treatments, more use in male hypogonadism, rising demand for fertility-related hormone therapy, growing diagnostic use as a tumor marker, and better drug formulations and dosing precision. - The report says infertility affected about 17.5% of the global adult population, or 1 in 6 people, in a 2023 World Health Organization estimate. - The report says delayed childbearing, obesity and smoking are contributing to infertility. - The report says chorionic gonadotropin supports pregnancy in the luteal phase and can stimulate testosterone production in men to improve sperm count. - A May 2024 report from Cofertility said egg freezing cycles rose nearly 40% from 2022 to 2023, signaling more use of fertility preservation services. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - More information is available in the company's sample report and the full market report.
Between the lines: - The forecast suggests a small but steady market, with growth coming more from expanding clinical use than from a single breakthrough product. - The emphasis on fertility treatment, male health and oncology diagnostics shows the market is benefiting from multiple demand streams rather than one specialty alone. - Retail pharmacy access and better dosing precision could make chorionic gonadotropin easier to use and more widely available.
What's next: - The market is expected to keep expanding through 2030 as infertility rates remain elevated and assisted reproductive technologies become more common. - New use cases in oncology diagnostics and male hormonal disorders could add to demand if adoption broadens. - Regional growth is likely to stay strongest in Asia-Pacific as North America remains the largest market base.
The bottom line: - Chorionic gonadotropin is a niche but expanding market, with fertility treatment needs driving most of the near-term growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Africa Daily Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.